Syantra Inc. to Unveil Revolutionary Insights on Breast Cancer at SABCS 2025

Syantra Inc. to Showcase Breakthrough Research on Immune Reprogramming in Breast Cancer at SABCS 2025

Calgary, AB, Dec. 2, 2025 – Syantra Inc., a prominent player in blood-based molecular diagnostics, has announced its participation in the upcoming San Antonio Breast Cancer Symposium (SABCS) scheduled from December 9 to 12, 2025, in San Antonio, Texas. The company aims to share significant findings regarding tumor-driven immune reprogramming, emphasizing the prospects of utilizing blood-based biomarkers for earlier detection of breast cancer.

During the symposium, Syantra will host a poster session on December 11 from 5:00 PM to 6:30 PM, showcasing a study titled _"Breast Cancer Drives Detectable Reprogramming in White Blood Cells and Platelets"_. Authors involved in this critical research include Olesya A. Kharenko, Karen Norek, Jacob Kennard, Kenneth Fuh, Robert D. Shepherd, Kristina D. Rinker, among others, from Syantra Inc. and the University of Calgary.

The focus of the research lies in understanding how breast cancer influences gene expression in circulating white blood cells (WBCs) and platelets. Through comprehensive analyses of blood samples collected pre-biopsy from participants in Syantra's IDBC study, the research team has conducted transcriptomic profiling and pathway analysis to identify changes in immune cell behavior likely triggered by the tumor.

Dr. Olesya Kharenko, a principal scientist at Syantra, remarked, _"These findings indicate that breast cancer can reprogram normal white blood cells and platelets, prompting distinct immune and stress-response pathways akin to those observed in tumor cells."_ Such insights lay the groundwork for incorporating blood-based biomarkers as pivotal tools in detecting and possibly mitigating cancer-related immune dysfunction.

Notably, the study highlights the potential of tumor-educated blood signatures as powerful avenues for earlier, non-invasive detection of breast cancer. Dr. Kristina Rinker, Syantra's Chief Scientific Officer and a professor at the University of Calgary, stated, _"These findings strengthen the evidence that cancer leaves a detectable footprint across multiple blood compartments. Understanding this biology is essential to advancing blood-based diagnostic technologies that can improve patient care."_

The significance of external validation of Syantra’s scientific contributions at renowned events like SABCS cannot be overstated, especially as the company approaches the commercialization of its first product, _Onco-ID Breast_, set to launch in 2026. According to Rob Lozuk, Syantra’s CEO, _"The continued validation of our science at world-leading events like SABCS is foundational as we approach the commercialization of our first product, Onco-ID Breast in 2026."_

Furthermore, on December 12 at 11:45 AM, Dr. Kristina Rinker will participate in the Alamo Breast Cancer Foundation's educational panel titled _"Understanding Diagnostic Tools and Tests for Making Appropriate Treatment Decisions"_. This engagement provides an excellent platform for her to share insights on how blood-based diagnostics and immune biology are transforming the early detection of breast cancer, thus revolutionizing the approach clinicians have towards identifying and treating the disease before it can progress. Her involvement underscores Syantra's commitment to advancing scientific knowledge while also empowering patients and educating communities about precision oncology.

About Syantra Inc.

Founded by a team of experts in biomedical engineering and medicine based in Calgary, and supported by leading clinicians, Syantra Inc. is a cutting-edge precision biotechnology firm that is pioneering a platform aimed at reshaping cancer detection and management. For additional information, visit Syantra's website.